Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review
Immunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. T...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/5/1179 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850258147044753408 |
|---|---|
| author | Nigel P. Murray |
| author_facet | Nigel P. Murray |
| author_sort | Nigel P. Murray |
| collection | DOAJ |
| description | Immunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. This article reviews the immunosuppressive effects of prostate cancer and possible uses of various types of immunotherapies. It also considers when would be the optimal time to employ this type of therapy. |
| format | Article |
| id | doaj-art-10c57f5f93ff458db7d7014ead653af7 |
| institution | OA Journals |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-10c57f5f93ff458db7d7014ead653af72025-08-20T01:56:14ZengMDPI AGBiomedicines2227-90592025-05-01135117910.3390/biomedicines13051179Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date ReviewNigel P. Murray0Faculty of Medicine, Universidad Finis Terrae, Santiago 7501015, ChileImmunotherapy alone or in combination with chemotherapy or radiotherapy is the frontline treatment for melanoma and lung cancer. However, its role in prostate cancer is usually as a fourth-line treatment. It is usually employed in patients with metastasis, after androgen blockade and chemotherapy. This article reviews the immunosuppressive effects of prostate cancer and possible uses of various types of immunotherapies. It also considers when would be the optimal time to employ this type of therapy.https://www.mdpi.com/2227-9059/13/5/1179prostate cancerimmunotherapycancer vaccinesbiochemical failuremetastasis |
| spellingShingle | Nigel P. Murray Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review Biomedicines prostate cancer immunotherapy cancer vaccines biochemical failure metastasis |
| title | Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review |
| title_full | Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review |
| title_fullStr | Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review |
| title_full_unstemmed | Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review |
| title_short | Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review |
| title_sort | immunomodulation and immunotherapy for patients with prostate cancer an up to date review |
| topic | prostate cancer immunotherapy cancer vaccines biochemical failure metastasis |
| url | https://www.mdpi.com/2227-9059/13/5/1179 |
| work_keys_str_mv | AT nigelpmurray immunomodulationandimmunotherapyforpatientswithprostatecanceranuptodatereview |